Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials
LIPI is a significant independent prognostic marker for DCR in patients with STS treated with immunotherapy. In early-phase trials, LIPI could be used as a screening tool for stratification at inclusion. High neutrophil levels, which correlate with a poorer LIPI score, are likely associated with immunotherapy resistance. This relationship could explain the statistical impact of poor LIPI in the immunotherapy group.
Authors
- Axel Le Cesne
- Laura Mezquita (ORCID: https://orcid.org/0000-0003-0936-7338)
- Matthieu Roulleaux Dugage (ORCID: https://orcid.org/0000-0003-3192-2342)
- Benjamin Besse
- Édouard Auclin (ORCID: https://orcid.org/0000-0001-7039-4840)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Marianne Zoghbi (ORCID: https://orcid.org/0009-0008-3033-6775)
- Armelle Dufresne (ORCID: https://orcid.org/0000-0002-6637-3526)
- Patricia Pautier (ORCID: https://orcid.org/0000-0002-1459-268X)
- Isabelle Laure Ray-Coquard (ORCID: https://orcid.org/0000-0003-2472-8306)
- Mehdi Brahmi (ORCID: https://orcid.org/0000-0001-9904-166X)
- Elise F. Nassif (ORCID: https://orcid.org/0000-0003-3794-6759)
- Christophe Massard (ORCID: https://orcid.org/0000-0001-5505-0564)
- Bharti Patel
- Rastilav Bahleda
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Centre Léon Bérard (FR)
- Hospital Clínic de Barcelona (ES)
- Institut Bergonié (FR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3390/cancers16234053
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85